Angitia Biopharmaceuticals, a clinical-stage biotech firm with operations in the US and China, has secured $120 million in a Series C round of financing led by Bain Capital Life Sciences.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
